DHRNYSEhealth care

Danaher Corporation

$200.16上涨+1.11 (+0.56%)

研究复核截至: 2026年7月12日上午12:00 [UTC]

研究概览

Danaher Corporation operates in Life Sciences Tools and Services within the health care sector. This profile tracks its company-specific earnings drivers, valuation conditions, and primary-source risks.

開盤: 198.70
最高: 200.84
最低: 198.00
市值: 1416.67億
本益比: 38.79
52 週高點: --
股息: 0.800%
季度股利金額: --

近 3 个月价格

這裡展示近 3 個月價格走勢，幫助使用者先理解短期結構，再決定是否進入完整研究工作台。

投资论点

基础情景: Normalization in large-pharma and biotech ordering can restore growth in consumables and equipment. The base case remains conditional on biotech funding cycle staying manageable.
多头情景: Normalization in large-pharma and biotech ordering can restore growth in consumables and equipment. A large installed base in life sciences and diagnostics supports repeat reagent, service and consumable demand. Disciplined integration of Masimo can broaden specialty diagnostics and create operating-improvement opportunities.
空头情景: Weak biotechnology funding or customer destocking could delay a sustained order recovery. Large acquisitions can bring debt, execution, regulatory and synergy-realization risk. Procurement policy, local competition and macro weakness can pressure diagnostics and life-science demand.
论点失效条件: Reassess the thesis if weak biotechnology funding or customer destocking could delay a sustained order recovery.

关键催化剂

Bioprocessing recovery
Normalization in large-pharma and biotech ordering can restore growth in consumables and equipment.
Recurring consumables
A large installed base in life sciences and diagnostics supports repeat reagent, service and consumable demand.
Masimo integration
Disciplined integration of Masimo can broaden specialty diagnostics and create operating-improvement opportunities.

主要风险

Biotech funding cycle
Weak biotechnology funding or customer destocking could delay a sustained order recovery.
Acquisition integration
Large acquisitions can bring debt, execution, regulatory and synergy-realization risk.
China exposure
Procurement policy, local competition and macro weakness can pressure diagnostics and life-science demand.

估值解读

A durable compounder interpretation depends on bioprocessing normalization and recurring consumables outgrowing instrument cyclicality.
Acquisition upside should be weighed against integration demands, financing costs and the quality of core organic growth.